PHARVARIS
Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study. The co-founders of Pharvaris include an inventor of icatibant and the leadership from Jerini AG that developed icatibant for the treatment of HAE, now sold by Takeda under the brand name Firazyr®.
PHARVARIS
Industry:
Biotechnology Life Science Pharmaceutical
Founded:
2015-01-01
Address:
Zug, Zug, Switzerland
Country:
Switzerland
Website Url:
http://www.pharvaris.com
Total Employee:
11+
Status:
Active
Total Funding:
162.29 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome
Similar Organizations
Arctoris
Arctoris is a tech-enabled platform company in biotechnology, combining robotics & data science to accelerate drug discovery.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Core Biogenesis
Core Biogenesis is a biotechnology company building next-generation recombinant protein production technologies.
Eidos Therapeutics
Eidos Therapeutics is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
MiNA Therapeutics
MiNA Therapeutics is a clinical-stage biotechnology company developing therapeutic medicines to harness gene activation mechanisms.
OMass Technologies
OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics.
Syros Pharmaceuticals
Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits.
X4 Pharmaceuticals
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.
Current Advisors List
Board_member
2016-01-01
Board_member
2019-09-01
Current Employees Featured
Berndt Modig CEO @ Pharvaris
CEO
2015-10-01
Jochen Knolle Chief Scientific and Operating Officer @ Pharvaris
Chief Scientific and Operating Officer
2015-01-01
Anne Lesage Cofounder and Chief Early Development Officer @ Pharvaris
Cofounder and Chief Early Development Officer
2015-10-01
Morgan Conn Chief Business Officer @ Pharvaris
Chief Business Officer
2017-11-01
Joan Schmidt Chief Legal Officer @ Pharvaris
Chief Legal Officer
2022-01-01
Hans GCP Schikan Co-Founder and Vice Chairman of the Board @ Pharvaris
Co-Founder and Vice Chairman of the Board
2015-12-01
Founder
Stock Details
Investors List
Cormorant Asset Management
Cormorant Asset Management investment in Series C - Pharvaris
Venrock
Venrock investment in Series C - Pharvaris
venBio Partners
venBio Partners investment in Series C - Pharvaris
General Atlantic
General Atlantic investment in Series C - Pharvaris
Viking Global Investors
Viking Global Investors investment in Series C - Pharvaris
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Series C - Pharvaris
Foresite Capital
Foresite Capital investment in Series C - Pharvaris
Venrock
Venrock investment in Series B - Pharvaris
Foresite Capital
Foresite Capital investment in Series B - Pharvaris
Kurma Partners
Kurma Partners investment in Series B - Pharvaris
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-11 | Pharvaris Appoints Joan Schmidt, J.D., as Chief Legal Officer |
Official Site Inspections
http://www.pharvaris.com Semrush global rank: 5.52 M Semrush visits lastest month: 1.54 K
- Host name: cloudproxy10157.sucuri.net
- IP address: 192.124.249.157
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Pharvaris"
About Us - Pharvaris
Pharvaris is a clinical-stage company focused on bringing oral bradykinin B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target 1,2,3 with novel, oral small molecules, the Pharvaris team is advancing …See details»
Investor Relations - Pharvaris N.V.
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. …See details»
Pharvaris - Crunchbase Company Profile & Funding
PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study. The …See details»
Pharvaris gains EU orphan designation for angioedema drug
1 day ago Pharvaris aims to provide an alternative to injectable treatments for bradykinin-mediated angioedema with the convenience of an oral therapy. The company has reported …See details»
Org Chart Pharvaris - The Official Board
Organizational Chart of Pharvaris. Pharvaris www.pharvaris.com. has 13 executives +31 7591 4441; Add an executive. Pharvaris (PHVS) News . Anything missing? We search for you. Print …See details»
Pharvaris Management Team | Org Chart - RocketReach
Pharvaris employs 120 employees. The Pharvaris management team includes Berndt Modig (Co-founder and CEO), Annick Deschoolmeester (Chief Human Resources Officer), and Emily …See details»
Pharvaris - Funding, Financials, Valuation & Investors - Crunchbase
Pharvaris is registered under the ticker NASDAQ:PHVS . Their stock opened with $20.00 in its Feb 4, 2021 IPO. Stock Symbol NASDAQ:PHVS ; Valuation at IPO $636.8M; Money Raised at …See details»
Pharvaris N.V. (PHVS) Company Profile & Facts - Yahoo Finance
See the company profile for Pharvaris N.V. (PHVS) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
Pharvaris Company Profile | Management and Employees List
Pharvaris Profile and History. Pharvaris is a clinical-stage company focused on bringing oral B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel …See details»
Pharvaris - LinkedIn
The #Pharvaris team will be in San Diego for the 2025 American Academy of Allergy, Asthma and Immunology - AAAAI/World Allergy Organization Joint Congress where three posters highlighting novel ...See details»
Pharvaris - Contacts, Employees, Board Members, Advisors & Alumni
Pharvaris is a clinical-stage biomedical company focused on bringing oral bradykinin B2-receptor antagonists to patients. ... Experience the new Crunchbase, powered by AI . Experience the …See details»
Pharvaris Company Profile - Office Locations, Competitors, …
Oct 29, 2024 Pharvaris is a clinical-stage company focused on the discovery and development of oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) …See details»
Pharvaris GmbH – Swiss Biotech
Pharvaris is a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. Pharvaris aspires to offer people with all types …See details»
Pharvaris 2025 Company Profile: Stock Performance & Earnings
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically …See details»
Pharvaris - businessabc.net
Mar 26, 2025 Pharvaris. We value your privacy. We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", …See details»
Pharvaris Announces Orphan Designation Granted to …
16 hours ago Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated …See details»
News Releases - Pharvaris N.V.
Jan 13, 2025 Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025 ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), …See details»
Pharvaris - Overview, News & Similar companies | ZoomInfo.com
Who is Pharvaris. Pharvaris is a clinical-stage company focused on bringing oral B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small …See details»
Deucrictibant Clinical Trials in HAE - Pharvaris
Pharvaris is committed to serving patients’ health needs by developing safe and effective therapies and making them available for use as quickly as possible. We believe that controlled …See details»
Pharvaris Announces Orphan Designation Granted to …
16 hours ago About Pharvaris Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin …See details»